= Abstract = Although the increasing incidence of central precocious puberty (CPP) in Korea has recently raised public concerns about health and growth problems, there are many areas of uncertainty regarding the pathogenesis, diagnosis, and management of CPP. In this paper, we review the definition of precocity, the assessment of CPP, and the hormonal abnormalities that support the diagnosis. In addition, we review the practical guidelines regarding the clinical use of gonadotropin-releasing hormone analogs in children with CPP. Indications for treatment, determination of dosage, monitoring during treatment, and discontinuation of therapy are discussed. (Korean J Pediatr 2010;53:294-299) 
Introduction
Puberty is a transitional period characterized by rapid physiological changes, including growth spurts and maturation of the gonads and the brain. It entails progression from the first appearance of secondary sexual characteristics to full sexual maturation and fertility. While it is known that the onset of puberty is initiated by awakening of complex neuroendocrine machinery and an increase in pulsatile secretion of gonadotropin-releasing hormone (GnRH) in the hypothalamic-pituitary-gonadal (HPG) axis, the primary mechanisms are incompletely understood. The time of onset of puberty and its course are influenced by genetic factors and are modified by environmental factors, including socioeconomic factors, nutrition, general health, geography, altitude, intrauterine conditions, stress, climate conditions, and the light-dark cycle 1) . Puberty is considered precocious when the onset of puberty begins before the age of 8 years in girls and before the age of 9 years in boys 2) . Precocious puberty is divided into two classes: central precocious puberty (CPP) and pseudoprecocious puberty.
CPP is caused by premature reactivation of the HPG axis, while pseudoprecocious puberty is unrelated to activation of the HPG axis. In our series of 948 patients referred for evaluation of signs of precocious puberty, the final diagnoses were as follows: early puberty (39%), premature thelarche (31%), CPP (27%), and pseudoprecocious puberty (1%) 3) . About 95% of precocious puberty is in females and 90% of CPP in girls is idiopathic 3) . Children with precocious puberty may experience problems in growth and . The increasing incidence of precocious puberty has raised public concerns over health and growth problems. This review summarizes the optimal use of GnRHas in children with CPP. .
Hormonal criteria
When the patient is suspected of having precocious pub- .
The GnRH stimulation test can be performed by administration of GnRH (serial samples at 30 minutes interval for 120 minutes after 100 g intravenous infusion) or a GnRHa μ such as aqueous leuprolide (single sample at 60 minutes).
Although peak LH levels show an overlap between prepubertal and early pubertal children, a prepubertal limit of peak LH at 3.3 to 5.0 IU/L has been suggested 9, 10) . According to the Health Insurance Review and Assessment
Service of Korea, a peak LH higher than 5.0 IU/L can be considered a pubertal range. In contrast, FSH levels are not helpful diagnostically. However, the measurements of the LH/FSH ratio after GnRH stimulation may help to differentiate progressive CPP from nonprogressive variants.
Daytime estradiol concentration levels higher than 10 pg/mL in girls or testosterone levels higher than 25 ng/dL in boys represent pubertal conditions 11) . However, the serum level of sex hormone may be fluctuating in the early pubertal period or in the normal cyclic fashion of CPP.
Brain magnetic resonance imaging
Unsuspected intracranial organic lesions in CPP have been reported in 8% of girls and 40% of boys 12, 13) . Our study showed that 10.7% of girls and 42.8% of boys with CPP had intracranial pathology 3) . The incidence of intracranial pathology with CPP decreases with age 12, 13) . Magnetic resonance imaging of the sella is indicated in all boys with CPP, girls less than 6 years of age with CPP, girls with rapidly progressive CPP, or neurologic findings.
Pelvic ultrasonography
Pelvic ultrasonography is helpful for differentiating CPP from premature thelarche. Girls with CPP have an increased uterine length (more than 3.4-4.0 cm) and ovarian volume (more than 1 3 mL) relative to girls in prepubertal period -or with premature thelarche 14, 15) . Pelvic ultrasonography is also indicated to rule out abdominal or pelvic masses when pseudoprecocious puberty is suspected. (Table 1) 5)
. From these criteria, it is obvious that careful follow-up examination should be made before a decision regarding the indication for treatment.
Currently available GnRHas
GnRH agonistic analogs were developed throughout the 1970s and 1980s and were first applied in the management of CPP patients in 1981 16, 17) . GnRHas suppress the serum 18, 19) , but a randomized comparative study has not yet been conducted.
Dose of GnRHas
The choice of the optimal dose of GnRHas at the start of treatment is controversial. A study in Japan, where leuprolide was first developed, recommended a dose of more than 30 g/kg to suppress gonadotropins μ 20) . . Treatment is considered adequate if the estradiol level becomes prepubertal 24) or if the peak LH is below 2.3 IU/L after a classical GnRH test or below 6.6 IU/L 2 hours after administration of depot .
Discontinuation of GnRHas
The decision to discontinue GnRHas treatment depends upon the primary goals of therapy, which may include prevention of short adult height, decreasing psychosocial distress, and facilitation of care of the developmentally delayed child 6) . In terms of improving the height potential of girls, discontinuation of the therapy at the chronological age of 11 years 26) or bone age of 12.0 12.5 years of age -27) is generally suggested. However, bone age is not an appropriate single variable because it is unreliable as a predictor of height gain after treatment 28) .
Therapeutic agents that can be combined with GnRHas
Growth hormone (GH) can be added if the growth velo- .
Adverse reactions
Administration of GnRHas produces relatively minimal adverse reactions. Headaches and menopausal symptoms such as hot flashes may be associated with therapy. Local complications, including sterile abscess, occur in 10% to 15% of patients 18) . Although there is a concern about the possible risks of obesity and osteoporosis during and after treatment, longitudinal studies showed that GnRHas do not increase the incidence of obesity or osteoporosis [29] [30] [31] .
Effect of GnRHas treatment on final height
GnRHas have been used in the treatment of CPP for more . When GH is added, height gain can be increased to 2.0 cm above the pretreatment height prediction for each year of therapy 33) .
Long-term outcome after GnRHas treatment
Long-term studies have reported that gonadal function is reactivated soon after cessation of treatment. The mean time for onset of menstruation after discontinuation of therapy is 16 months (range 2-61 months) 31) . A regular ovarian cycle occurred in 60% to 96% of the patients, which is compatible with the normal pattern of menses at this age. Infertility has not been reported. There is no evidence that CPP increases the risk of hirsutism and/or polycystic ovary syndrome relative to the normal population 34) . Only limited studies are available on the effects of psychosocial development after GnRHas treatment 35) . Further studies that employ standardized tools are needed.
GnRHas treatment in conditions other than CPP
GnRHas treatment in early puberty
Early puberty in girls is defined as onset of puberty at an age of 8-9 years. Some patients with early puberty may experience attenuated height potential and psychosocial problems 36) . However, routine use of GnRHas in early puberty is not suggested because the effect of GnRHas on final height is equivocal and because of the possibility of additional adverse effects 36) . GnRHas therapy in early puberty should be restricted to patients for whom a dramatic decrease in height is predicted. This therapy should be conducted over a 6-month follow-up period for the advanced and rapidly progressive forms 37) .
GnRHas treatment in GH deficiency or idiopathic short stature
Retrospective and prospective studies evaluating the effect of administering GnRHas with GH in patients with GH deficiency or idiopathic short stature have provided controversial results [38] [39] [40] . Combined therapy with GnRHas and GH in patients with GH deficiency or idiopathic short stature is not presently suggested 8) .
Conclusion
GnRHas therapy is the standard treatment modality for GnRHas causes obesity, osteoporosis, or severe long-term sequelae that lead to infertility. GnRHas treatment for conditions other than CPP is not recommended.
